Phenytoin oral capsule is available as brand-name drugs and as a generic drug. Brand names: Phenytek, Dilantin. Phenytoin comes in three oral forms: extended-release oral capsule, chewable tablet, and ...

Avoid drinking alcohol while taking Phenytoin because it can cause side effects such as drowsiness, dizziness and increased risk of seizures (1 Trusted Source National Institute on Alcohol and ...

Discover comprehensive details about Phenytoin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Phenytoin 50mg/mL; contains alcohol, propylene glycol. Increased cardiovascular risk associated with rapid infusion; monitor during and after therapy; rate reduction or discontinuation may be needed.

Marketed formulations of extended phenytoin sodium -- long a difficult medication to titrate because of its unique absorption and saturable elimination pharmacokinetics -- may not be bioequivalent, ...

To evaluate the efficacy of topical phenytoin solution in treating pressure ulcers among patients with spinal cord disorders and to evaluate the systemic absorption of topical phenytoin. Twenty-eight ...

Phenytoin remains a mainstay in the management of seizure disorders but presents considerable challenges owing to its narrow therapeutic index, high protein binding and nonlinear pharmacokinetics.

Phenytoin is a well known antiepileptic agent widely used throughout the world. In a new study, researchers utilized DNA microarrays to investigate the molecular underpinnings of the potential ...

The woman had refractory epilepsy and mental insufficiency since 15 years of age following an episode of encephalitis. Her epilepsy showed a fair response to adjunctive vagus nerve stimulation ...

Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling two (2) lots of Phenytoin Oral Suspension USP, 125 mg/5 mL both in 237 mL bottles, to the consumer level. Phenytoin ...

Phenytoin 50mg/mL; contains alcohol, propylene glycol. Increased cardiovascular risk associated with rapid infusion; monitor during and after therapy; rate reduction or discontinuation may be needed.